Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.
Bile acid sequestrants (BAS) continue to command a position in the treatment of dyslipidemias 25 years after their introduction. Partial diversion of the enterohepatic circulation using BAS depletes the endogenous bile acid pool by approximately 40%, thus stimulating an increase in bile acid synthesis from cholesterol, which lowers low-density lipoprotein cholesterol (LDL-C) by 15 to 26%. Three BAS are currently used for treating hypercholesterolemia in the United States: the conventional sequestrants, cholestyramine and colestipol, and the specifically engineered BAS, colesevelam hydrochloride (HCl). Compared with conventional BAS, colesevelam HCl has enhanced specificity, greater affinity, and higher capacity for binding bile acids, due to its polymer structure engineered for bile acid sequestration. BAS are not absorbed by the intestine and thus have no systemic drug-drug interactions, but may interfere with the absorption of some drugs. Although BAS monotherapy effectively lowers LDL-C, combination therapy, especially with BAS and statins, is becoming increasingly common due to complementary mechanisms of action. Low-dose statin plus BAS combinations lead to greater or similar LDL-C reductions compared with high-dose statin monotherapy and may have a better safety profile. Combinations of BAS with nonstatin lipid-lowering agents, including niacin, fibrates, and cholesterol absorption inhibitors, may be useful in those patients who require intensive lipid-lowering, but are statin intolerant. BAS treatment can significantly reduce coronary artery disease (CAD) progression and the risk of CAD-associated outcomes. It is also becoming clear that BAS and other therapies that manipulate the bile acid synthetic pathway may have clinically useful therapeutic effects on other metabolic disorders including type 2 diabetes.
Insull
William
W
Baylor College of Medicine, Lipid Research Clinic, Houston, TX 77030, USA. winsull@bcm.tmc.edu
D000499:Allylamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000627:therapeutic use*; D002784:Cholesterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069472:Colesevelam Hydrochloride; D003084:Colestipol / Q000627:therapeutic use; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D016896:Treatment Outcome
D001647:Bile Acids and Salts; D000960:Hypolipidemic Agents; D008055:Lipids; C072855:cholesterylamine; D000499:Allylamine; D002784:Cholesterol; D003084:Colestipol; D000069472:Colesevelam Hydrochloride